1M6MYTD1A5AMAX
Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 8,78 € (-64,71 %). La mediana es de 8,78 € (-64,71 %).
| Comprar |
11 |
| Mantener |
8 |
| Vender |
0 |
Noticias Ir al feed de noticias
Mersana Therapeutics releases quarterly results for Sept. 30, 2025 – analysts expect smaller loss per share
Mersana Therapeutics will publish results for the quarter ended Sept. 30, 2025 on Nov. 14, 2025. Eight analysts on average expect earnings per share of -$1.544, an improvement of 31.38% from the year-ago quarter (-$2.250). Nine analysts estimate quarterly revenue at an average of $14.2 million (up 12.7% from $12.6 million). For the current fiscal year analysts expect on average a loss of -$6.784 per share and revenue of around $25.3 million (prior year: $40.5 million). » Más en finanzen.net
Datos financieros de la empresa
| (EUR) | septiembre de 2025 | |
|---|---|---|
| Ingresos | 9,38 M | - |
| Beneficio bruto | 9,38 M | - |
| Beneficio neto | -6,43 M | - |
| EBITDA | -6,02 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 127,62 M € |
Número de acciones | 5 M |
Máximo/mínimo de 52 semanas | 26,68 € - 4,57 € |
| Dividendos | No |
Beta | 0,43 |
Ratio P/E | -2,59 |
Ratio PEG | -0,35 |
Ratio P/B | -2,44 |
Ratio P/S | 8,64 |
Perfil de la empresa
| Nombre | Mersana Therapeutics Inc |
| CEO | Martin H. Huber |
| Empleados | 102 |
